Abstract
A novel pH-responsive drug carrier for the delivery of specific Docetaxel (DTX) administration is developed based on a zeolitic imidazolate framework (ZIF-8). Aminating the surface of ZIF-8 is allowed for the conjugation of folic acid (FA). Several spectroscopic studies characterized the newly fabricated DTX-encapsulated folic acid-embedded ethylene diamine (ED) ZIF-8 nanocomposites (DTX/FA@ED-ZIF-8). It has excellent chemical stability and high drug-loading efficiency. DTX from the folic acid-embedded aminated ZIF-8 (FA@ED-ZIF-8) is three-fold more efficient under acidic pH (5.0) than in physiological settings (pH 7.4), according to in vitro drug release tests. DTX/FA@ED-ZIF-8 exhibited cytotoxicity of 76.8% in an MTT experiment conducted in A549 and H1299 cells. Cell morphological and nuclear staining were investigated in the fabricated samples to support the MTT experiments. Further, the apoptosis mode of cell death was examined using Annexin V-FITC and PI by flow cytometry. These findings indicate that FA@ED-ZIF-8 holds great potential as a drug carrier for precise dosing.
Graphical abstract
Similar content being viewed by others
Data availability
Not applicable.
References
S. Dai, T. Liu, Y.-Y. He, Y. Huang, L. Wang, F. Luo, Y. Li, Pan-cancer analysis of LINC02535 as a potential biomarker and its oncogenic role in lung adenocarcinoma. Heliyon. 8, e12108 (2022)
M. Yuan, Y. Zhao, H.-T. Arkenau, T. Lao, L. Chu, Q. Xu, Signal pathways and precision therapy of small-cell lung cancer. Signal Transduct. Target. Ther. 7, 187 (2022)
B.T. Li, E.F. Smit, Y. Goto, K. Nakagawa, H. Udagawa, J. Mazières, M. Nagasaka, L. Bazhenova, A.N. Saltos, E. Felip, Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N. Engl. J. Med. 386, 241–251 (2022)
Z. Wang, Q. Sun, B. Liu, Y. Kuang, A. Gulzar, F. He, S. Gai, P. Yang, J. Lin, Recent advances in porphyrin-based MOFs for cancer therapy and diagnosis therapy. Coord. Chem. Rev. 439, 213945 (2021)
M. Ibrahim, R. Sabouni, G.A. Husseini, Anti-cancer drug delivery using metal organic frameworks (MOFs). Curr. Med. Chem. 24, 193–214 (2017)
L.-Q. Fu, X.-Y. Chen, M.-H. Cai, X.-H. Tao, Y.-B. Fan, X.-Z. Mou, Surface engineered metal-organic frameworks (MOFs) based novel hybrid systems for effective wound healing: a review of recent developments. Front. Bioeng. Biotechnol. 8, 576348 (2020)
S. Zhang, F. Rong, C. Guo, F. Duan, L. He, M. Wang, Z. Zhang, M. Kang, M. Du, Metal–organic frameworks (MOFs) based electrochemical biosensors for early cancer diagnosis in vitro. Coord. Chem. Rev. 439, 213948 (2021)
M.R. Saeb, N. Rabiee, M. Mozafari, F. Verpoort, L.G. Voskressensky, R. Luque, Metal–organic frameworks (MOFs) for cancer therapy. Materials. 14, 7277 (2021)
H. Zhang, Q. Li, R. Liu, X. Zhang, Z. Li, Y. Luan, A versatile prodrug strategy to in situ encapsulate drugs in MOF nanocarriers: a case of cytarabine-IR820 prodrug encapsulated zif-8 toward chemo-photothermal therapy. Adv. Funct. Mater. 28, 1802830 (2018). https://doi.org/10.1002/adfm.201802830
M. Xu, Y. Hu, W. Ding, F. Li, J. Lin, M. Wu, J. Wu, L.-P. Wen, B. Qiu, P.-F. Wei, Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance. Biomaterials 258, 120308 (2020)
H.N. Abdelhamid, Zeolitic imidazolate frameworks (ZIF-8) for biomedical applications: a review. Curr. Med. Chem. 28, 7023–7075 (2021)
Q. Wang, Y. Sun, S. Li, P. Zhang, Q. Yao, Synthesis and modification of ZIF-8 and its application in drug delivery and tumor therapy. RSC Adv. 10, 37600–37620 (2020)
H. Xie, X. Liu, Z. Huang, L. Xu, R. Bai, F. He, M. Wang, L. Han, Z. Bao, Y. Wu, Nanoscale zeolitic imidazolate framework (ZIF)–8 in cancer theranostics: current challenges and prospects. Cancers (Basel). 14, 3935 (2022)
Y.-T. Qin, H. Peng, X.-W. He, W.-Y. Li, Y.-K. Zhang, pH-responsive polymer-stabilized ZIF-8 nanocomposites for fluorescence and magnetic resonance dual-modal imaging-guided chemo-/photodynamic combinational cancer therapy. ACS Appl. Mater. Interfaces 11, 34268–34281 (2019)
J. Yan, Y. Wang, X. Zhang, S. Liu, C. Tian, H. Wang, Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid–polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Deliv. 23, 1757–1762 (2016)
J. Cai, K. Qian, X. Zuo, W. Yue, Y. Bian, J. Yang, J. Wei, W. Zhao, H. Qian, B. Liu, PLGA nanoparticle-based docetaxel/LY294002 drug delivery system enhances antitumor activities against gastric cancer. J. Biomater. Appl. 33, 1394–1406 (2019)
D. Liu, Z. Liu, L. Wang, C. Zhang, N. Zhang, Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf. B 85, 262–269 (2011). https://doi.org/10.1016/j.colsurfb.2011.02.038
L. Di Lauro, F. Belli, M.G. Arena, S. Carpano, G. Paoletti, D. Giannarelli, M. Lopez, Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann. Oncol. 16, 1498–1502 (2005). https://doi.org/10.1093/annonc/mdi281
Q. Wang, Y.-T. Yen, C. Xie, F. Liu, Q. Liu, J. Wei, L. Yu, L. Wang, F. Meng, R. Li, B. Liu, Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells. Drug Deliv. 28, 510–519 (2021). https://doi.org/10.1080/10717544.2021.1886378
A. Al Saqr, S.U. Wani, H.V. Gangadharappa, M.F. Aldawsari, E.-S. Khafagy, A.S.A. Lila, Enhanced cytotoxic activity of docetaxel-loaded silk fibroin nanoparticles against breast cancer cells. Polym. (2021). https://doi.org/10.3390/polym13091416
J. Ai, Y. Xu, D. Li, Z. Liu, E. Wang, Folic acid as delivery vehicles: targeting folate conjugated fluorescent nanoparticles to tumors imaging. Talanta 101, 32–37 (2012)
H. Samadian, S. Hosseini-Nami, S.K. Kamrava, H. Ghaznavi, A. Shakeri-Zadeh, Folate-conjugated gold nanoparticle as a new nanoplatform for targeted cancer therapy. J. Cancer Res. Clin. Oncol. 142, 2217–2229 (2016)
N. Shahabadi, M. Razlansari, H. Zhaleh, K. Mansouri, Antiproliferative effects of new magnetic pH-responsive drug delivery system composed of Fe3O4, CaAl layered double hydroxide and levodopa on melanoma cancer cells. Mater. Sci. Eng. C 101, 472–486 (2019). https://doi.org/10.1016/j.msec.2019.04.004
H. Li, Y. Wang, X. He, J. Chen, F. Xu, Z. Liu, Y. Zhou, A green deep eutectic solvent modified magnetic titanium dioxide nanoparticles for the solid-phase extraction of chymotrypsin. Talanta 230, 122341 (2021). https://doi.org/10.1016/j.talanta.2021.122341
M. Chelladurai, R. Sahadevan, G. Margavelu, S. Vijayakumar, Z.I. González-Sánchez, K. Vijayan, D. Balaji, Anti-skin cancer activity of Alpinia calcarata ZnO nanoparticles: characterization and potential antimicrobial effects. J. Drug Deliv. Sci. Technol. 61, 102180 (2021). https://doi.org/10.1016/j.jddst.2020.102180
A. Nagarsenkar, L. Guntuku, S.D. Guggilapu, S. Gannoju, V.G.M. Naidu, N.B. Bathini, Synthesis and apoptosis inducing studies of triazole linked 3-benzylidene isatin derivatives. Eur. J. Med. Chem. 124, 782–793 (2016). https://doi.org/10.1016/j.ejmech.2016.09.009
A.H.Y. Kwok, Y. Wang, W.S. Ho, Cytotoxic and pro-oxidative effects of Imperata cylindrica aerial part ethyl acetate extract in colorectal cancer in vitro. Phytomedicine 23, 558–565 (2016). https://doi.org/10.1016/j.phymed.2016.02.015’
R. Foldbjerg, D.A. Dang, H. Autrup, Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch. Toxicol. 85, 743–750 (2011). https://doi.org/10.1007/s00204-010-0545-5
R. Prabhu, R. Anjali, G. Archunan, N.M. Prabhu, A. Pugazhendhi, N. Suganthy, Ecofriendly one pot fabrication of methyl gallate@ ZIF-L nanoscale hybrid as pH responsive drug delivery system for lung cancer therapy. Process Biochem. 84, 39–52 (2019)
Z. Abbasi, E. Shamsaei, X.-Y. Fang, B. Ladewig, H. Wang, Simple fabrication of zeolitic imidazolate framework ZIF-8/polymer composite beads by phase inversion method for efficient oil sorption. J. Colloid Interface Sci. 493, 150–161 (2017). https://doi.org/10.1016/j.jcis.2017.01.006
M. Sandomierski, M. Jakubowski, M. Ratajczak, A. Voelkel, Zeolitic Imidazolate Framework-8 (ZIF-8) modified titanium alloy for controlled release of drugs for osteoporosis. Sci. Rep. 12, 9103 (2022). https://doi.org/10.1038/s41598-022-13187-0
T. Sathiya Kamatchi, M.K. Mohamed Subarkhan, R. Ramesh, H. Wang, J.G. Małecki, Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes. Dalt. Trans. 49, 11385–11395 (2020). https://doi.org/10.1039/D0DT01476A
R. Raj Kumar, M.K. Mohamed Subarkhan, R. Ramesh, Synthesis and structure of nickel(ii) thiocarboxamide complexes: effect of ligand substitutions on DNA/protein binding, antioxidant and cytotoxicity. RSC Adv. 5, 46760–46773 (2015). https://doi.org/10.1039/C5RA06112A
D.P. Dorairaj, J. Haribabu, M. Dharmasivam, R.E. Malekshah, M.K. Mohamed Subarkhan, C. Echeverria, R. Karvembu, Ru(II)-p-cymene complexes of furoylthiourea ligands for anticancer applications against breast cancer cells. Inorg. Chem. 62, 11761–11774 (2023). https://doi.org/10.1021/acs.inorgchem.3c00757
M.K. Mohamed Subarkhan, R. Ramesh, Y. Liu, Synthesis and molecular structure of arene ruthenium(II) benzhydrazone complexes: impact of substitution at the chelating ligand and arene moiety on antiproliferative activity. New J. Chem. (2016). https://doi.org/10.1039/c6nj01936f
S. Balaji, M.K. Mohamed Subarkhan, R. Ramesh, H. Wang, D. Semeril, Synthesis and structure of arene Ru(II) N∧O-chelating complexes: in vitro cytotoxicity and cancer cell death mechanism. Organometallics 39, 1366–1375 (2020). https://doi.org/10.1021/acs.organomet.0c00092
M.K. Mohamed Subarkhan, L. Ren, B. Xie, C. Chen, Y. Wang, H. Wang, Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo. Eur. J. Med. Chem. (2019). https://doi.org/10.1016/j.ejmech.2019.06.061
M.K.M. Subarkhan, R. Ramesh, Ruthenium(II) arene complexes containing benzhydrazone ligands: synthesis, structure and antiproliferative activity. Inorg. Chem. Front. 3, 1245–1255 (2016). https://doi.org/10.1039/c6qi00197a
M.S. Mohamed Kasim, S. Sundar, R. Rengan, Synthesis and structure of new binuclear ruthenium(II) arene benzil bis(benzoylhydrazone) complexes: investigation on antiproliferative activity and apoptosis induction. Inorg. Chem. Front. 5, 585–596 (2018). https://doi.org/10.1039/c7qi00761b
R. Pilliadugula, J. Haribabu, M.K. Mohamed Subarkhan, C. Echeverria, R. Karvembu, N. Gopalakrishnan, Effect of morphology and (Sn, Cr) doping on in vitro antiproliferation properties of hydrothermally synthesized 1D GaOOH nanostructures. J. Sci. Adv. Mater. Dev. 6, 351–363 (2021). https://doi.org/10.1016/j.jsamd.2021.03.003
S. Swaminathan, J. Haribabu, M.K. Mohamed Subarkhan, D. Gayathri, N. Balakrishnan, N. Bhuvanesh, C. Echeverria, R. Karvembu, Impact of aliphatic acyl and aromatic thioamide substituents on the anticancer activity of Ru(ii)-p-cymene complexes with acylthiourea ligands—in vitro and in vivo studies. Dalt. Trans. 50, 16311–16325 (2021). https://doi.org/10.1039/D1DT02611A
K. Giriraj, M.S. Mohamed Kasim, K. Balasubramaniam, S.K. Thangavel, J. Venkatesan, S. Suresh, P. Shanmugam, C. Karri, Various coordination modes of new coumarin Schiff bases toward Cobalt (III) ion: Synthesis, spectral characterization, in vitro cytotoxic activity, and investigation of apoptosis. Appl. Organomet. Chem. 36, e6536 (2022). https://doi.org/10.1002/aoc.6536
G. Kalaiarasi, M. Mohamed Subarkhan, C.K. Fathima Safwana, S. Sruthi, T. Sathiya Kamatchi, B. Keerthana, S.L. Ashok Kumar, New organoruthenium(II) complexes containing N, X-donor (X = O, S) heterocyclic chelators: synthesis, spectral characterization, in vitro cytotoxicity and apoptosis investigation. Inorg. Chim. Acta 535, 120863 (2022). https://doi.org/10.1016/j.ica.2022.120863
S. Swaminathan, J. Haribabu, M.K. Mohamed Subarkhan, G. Manonmani, K. Senthilkumar, N. Balakrishnan, N. Bhuvanesh, C. Echeverria, R. Karvembu, Coordination behavior of acylthiourea ligands in their Ru(II)–benzene complexes─structures and anticancer activity. Organometallics 41, 1621–1630 (2022). https://doi.org/10.1021/acs.organomet.2c00127
Funding
This project was supported by Researchers Supporting Project number (RSP2024R383), King Saud University, Riyadh, Saudi Arabia.
Author information
Authors and Affiliations
Contributions
The authors confirm their contribution to the paper as follows: Arunachalam Chinnathambi and Sulaiman Ali Alharbi: Conceptualization, Writing-Reviewing, and Editing. Sridhar Muthusami: Software, Data curation, Investigation, Formal analysis, Software, Validation. Mohankumar Ramar: Visualization, Methodology. Palanisamy Arulselvan: Supervision. All authors reviewed the results and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declared no conflicts of interest regarding the publication of this paper.
Consent to participate
All authors have read and agreed to the submitted version of the manuscript.
Consent for publication
Not applicable to this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chinnathambi, A., Alharbi, S.A., Ramar, M. et al. Fabrication of folic acid-embedded aminated drug encapsulated zeolitic imidazolate framework as promising drug delivery system for lung cancer. Journal of Materials Research (2024). https://doi.org/10.1557/s43578-024-01328-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1557/s43578-024-01328-2